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Abstract
Background: We previously demonstrated that the matrix metalloproteinase-2 (MMP-2) contained an antigenic peptide
recognized by a CD8 T cell clone in the HLA-A*0201 context. The presentation of this peptide on class I molecules by human
melanoma cells required a cross-presentation mechanism. Surprisingly, the classical endogenous processing pathway did
not process this MMP-2 epitope.
Methodology/Principal Findings: By PCR directed mutagenesis we showed that disruption of a single disulfide bond
induced MMP-2 epitope presentation. By Pulse-Chase experiment, we demonstrated that disulfide bonds stabilized MMP-2
and impeded its degradation. Finally, using drugs, we documented that mutated MMP-2 epitope presentation used the
proteasome and retrotranslocation complex.
Conclusions/Significance: These data appear crucial to us since they established the existence of a new inhibitory
mechanism for the generation of a T cell epitope. In spite of MMP-2 classified as a self-antigen, the fact that cross-
presentation is the only way to present this MMP-2 epitope underlines the importance to target this type of antigen in
immunotherapy protocols.
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Introduction
Over the last 20 years, several human tumor antigens recognized
by autologous cytolytic T lymphocytes (CTL) have been character-
ized. Four classes of tumor antigens can be distinguished: cancer testis
antigens [1,2] differentiation antigens [3–5] mutated antigens [6] and
antigens aberrantly expressed in tumors [7,8]. To our knowledge,
little is known about the immunogenicity of these antigens. One ofthe
objectives of our work is to define tumor antigens involved in tumor
regression after cancer treatments [9,10].
We recently described the recognition, on about half HLA-A2
melanoma cell lines, of a new HLA-A2-restricted tumor antigen
derived from Matrix Metalloproteinase 2 (MMP-2) by a CTL clone
(M134.12) derived from Tumor Infiltrating Lymphocytes (TILs) of a
melanomapatient[9].Weshowedthatrecognitionofmelanomacells
by this CTL clone required MMP-2 secretion and cross-presentation
of the HLA-A2-restricted MMP-2560–568 epitope following avb3-
dependent endocytosis of secreted MMP-2 [9]. Surprisingly, the
MMP-2 epitope, located in the C-terminal extremity of the protein,
was poorly or not processed by the classical endogenous pathway,
since melanoma cells, which secrete MMP-2 but lack avb3 integrin
expression, and cells that synthesized MMP-2 but do not secrete it,
failed to be recognized by the specific CTL clone [9].
MMP-2 belongs to the gelatin-binding MMPs structural group.
This enzyme contains an amino-terminal signal sequence (Pre) that
directs it to the secretorypathwayvia theendoplasmicreticulum (ER)
and a propeptide (Pro) that maintains it as inactive zymogen [11].
MMP-2 comprises three contiguous fibronectin type II-like domains
that are inserted within its catalytic domain, one hemopexin domain,
and eight disulfide bridges (NCBI number P08253) [12]. MMP-2
secreted by normal and tumor cells has been shown to play a key role
in angiogenesis, tumor cell invasion, and metastasis, by promoting
degradationofExtracellularMatrix(ECM)andcleavageofcytokines,
growth factors, hormones, and cell receptors [13–16]. Because of its
role in melanoma progression, targeting the MMP-2 antigen by
immunotherapy might be particularly effective by limiting the
potential selection of antigen loss variants. Since many normal cells
express MMP-2, it is important to understand the mechanisms that
may prevent its endogenous presentation. To this end, using the
MMP-2 CTL clone we addressed which alterations of the MMP-2
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epitope upon transfection.
In this report, we provide evidence that disulfide bonds
contained in the MMP-2 protein prevent endogenous presentation
of the appropriate HLA-A2-restricted epitope. Furthermore, we
demonstrate that wild type MMP-2 is less sensitive to degradation
than mutated forms obtained by disulfide bond deletion.
Altogether these results identify a novel mechanism underlying
selective tumor cell recognition through cross-presentation of a
post-translationally modified ubiquitous protein.
Results
Deletion of the first 96 amino acids of MMP-2 restores
classical endogenous presentation of the MMP-2560–568
epitope
We previously described the recognition by a TIL-derived clone
of a MMP-2 derived HLA-A2-restricted peptide cross-presented
by avb3+ tumor cells. This clone, however failed to react against
avb3-negative HLA-A2+ cells expressing MMP-2, thus indicating
inefficient presentation of the MMP-2560–568 epitope by the
endogenous pathway. To address the underlying mechanisms of
these observations, we made progressive deletions of the MMP-2
cDNA from the 59 to the 39 end by PCR. COS-7 cells co-
transfected with plasmids coding for truncated variants of MMP-2
and HLA-A*0201 were then tested for their ability to stimulate
TNFa release from the relevant CTL clone (M134.12). The
minimally deleted construct thus obtained, corresponding to the
cDNA with a 1 to 96 aa deletion (D96MMP-2) restored expression
of the MMP-2 epitope (fig. 1A). This suggests that the region 1–96
of MMP-2 can impede endogenous presentation of the MMP-2
epitope localized in the C-terminal extremity of the protein.
Because sequence 1–96 of MMP-2 includes the secretion peptide
and part of the propeptide, we hypothesized that either the
compartmentalization of MMP-2 in the secretory pathway affects
routing to the proteasome [17] or that the propeptide contains an
inhibitory sequence blocking proteasomal degradation [18].
Deletion of the signal sequence or the propeptide
restores classical endogenous presentation
To address these two hypotheses, we constructed by PCR two
deleted forms of MMP-2 cDNA. One form harbored a signal
Figure 1. Various deletions and mutations of MMP-2 cDNA allow MMP-2560–568 epitope generation by the endogenous pathway in
HLA-A*0201 transfected COS-7 cells. COS-7 cells were cotransfected with HLA-A*0201 plasmid and with (A) plasmids coding for deleted MMP-2
or (B) plasmids coding for mutated MMP-2. 48 h later, M134.12 CTL clones were added to transfected COS-7 cells (E/T ratio 1:3) and the TNF response
was tested after 6 h on Wehi-13 cells. Standard deviations were obtained from duplicates. cDNA NA134-A corresponding to the C-terminal part of
MMP-2 contains MMP-2560-568 epitope and was used as positive control. Transfection efficiency was controlled with GFP transfected COS-7 cells. PS
corresponding to the signal sequence (pre), PD corresponding to the prodomaine (pro) and PEX corresponding to the hemopexine domaine of the
MMP-2. Data are representative of at least two independent experiments. Error bars indicate standard deviations of duplicates.
doi:10.1371/journal.pone.0011894.g001
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encoding the propeptide (D Pro). Both cDNAs (D Pre and D Pro)
led to effective MMP-2 epitope presentation by HLA-A*0201-
transfected COS-7 cells and subsequent CTL clone activation
(Fig. 1A). A potentially relevant shared feature of both MMP-2
products (D Pre and D Pro) is the absence of disulphide bonds.
Propeptide deletion (D Pro) eliminates a disulfide bridge (Cys
60 to
Cys
65) that is unique to proMMP-2 [12]. Moreover signal peptide
deletion (D Pre) should prevent MMP-2 translocation across the
endoplasmic reticulum (ER) and subsequent disulfide bond
formation. Therefore the efficient endogenous presentation of
MMP-2560–568 epitope from D Pre and D Pro constructs could be
due to misfolding of the truncated MMP-2 protein, resulting from
the absence of at least one disulfide bond.
Disulfide bond formation inhibits MMP-2560–568
endogenous presentation
To address the role of disulfide bond formation in modulation of
MMP-2 endogenous presentation more directly, we generated
mutants in which the disulfide bond contained in the prodomain
was disrupted. To this end we substituted cystein 60 and/or cystein
65 by an alanine. All mutated MMP-2 constructs (MMP-2 C60A or
MMP-2 C65A or MMP-2 C60A/C65A) allowed efficient endoge-
nous expression of the MMP-2 antigen when cotransfected with
HLA-A2.1 plasmids into COS-7 cells (Fig. 1B). To determine
whether this disulfide bond (Cys
60 to Cys
65) had a specific role in
preventing MMP-2 endogenous presentation, we mutated the cystein
codon of MMP-2 protein involved in the formation of another
disulfide bond (Cys
233 to Cys
247) located in the first fibronectin
domain of MMP-2 (MMP-2 C233A). As shown in Fig. 1B, this
mutated plasmid also induced MMP-2 epitope presentation by COS
cells. Therefore endogenous presentation of the MMP-2 antigen can
be induced by mutations impeding the formation of one disulfide
bond within MMP-2 propeptide or fibronectin domain.
Elimination of one disulfide bond restores MMP-2
endogenous presentation in human tumor cell lines
In order to determine whether the endogenous presentation of
MMP-2 by tumors cells is similarly affected by the removal of
disulfide bonds, we used HLA-A2 tumor cell lines that fail to
cross-present MMP-2 due to their lack of avb3 integrin [9]. We
previously showed that the expression of the avb3i n t e g r i ni s
necessary for exogenous presentation of MMP-2 antigen.
Transfection of plasmids encoding the four mutated forms of
MMP-2 (MMP-2C60A, MMP-2C65A, MMP-2C60/65A and
MMP-2C233A) into the M117 melanoma cell line or the non-
small cell lung carcinoma (NSCLC) 1355 cell line, induced
activation of the MMP-2- specific CTL clone (Fig. 2). Therefore,
as in COS-7 cells, endogenous presentation of the MMP-2560–568
epitope in human cells can be induced by mutational deletions
impeding formation of a single disulphide bond within this
protein.
Disulfide bond mutation does not impede MMP-2
secretion
To determine whether disulfide bond deletion could affect
MMP-2 protein secretion, we transfected MMP-2 cDNA with
mutated Cys codon into COS-7 cells. 48 h later, culture
supernatants were harvested and MMP-2 secretion was assessed
by detecting the enzymatic activity of MMP-2 by zymography
(Fig. 3A). All mutated proteins, with the exception of MMP-2
C233A, showed MMP-2 activity. Moreover western blotting
indicated that all mutated variants led to protein secretion
(Fig. 3B) even though MMP-2 C233A had no MMP-2 activity
(Fig. 3A). Therefore protein secretion does not impede endoge-
nous presentation of the MMP-2560–568 epitope. However, the
fact that MMP-2 C233A, which was secreted at a lower level
(Fig. 3B) induced higher clone activation (Fig. 1B), suggests that
protein secretion may nonetheless limit endogenous antigen
presentation.
Protein turn over is higher in Mutated MMP-2 mutants
versus WT MMP-2
The fact that disruption of a single disulfide bond within MMP-
2 was sufficient to induce endogenous presentation of the MMP-2
epitope, suggests that decreased conformational stability of MMP-
2 due to impaired disulfide bond formation lead to enhanced
endogenous degradation and subsequent MMP-2560–568 epitope
Figure 2. Disulfide bond deletion permit MMP-2560–568 epitope generation by the endogenous pathway in HLA-A*0201+/avb3-
human tumor cells. Melanoma cell line M117 and non small cell lung carcinoma line 1355 were transfected with plasmids coding for cystein
deleted MMP-2. 48 h later, M134.12 CTL clones were added to tumor cells (E/T ratio 1:3) and the TNF response was tested after 6 h on wehi-13 cells.
Standard deviations were obtained from duplicates. cDNA NA134-A corresponding to the C-terminal part of MMP-2, contains MMP-2560–568 epitope
and was used as positive control. Transfection efficiency was controlled with GFP transfected tumor cells. Data are representative of at least two
independent experiments. Error bars indicate standard deviations of duplicates. p,0.005 was considered significant.
doi:10.1371/journal.pone.0011894.g002
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whether disulfide bond integrity affects MMP-2 stability. Cells
were metabolically labeled with [
35S] methionine/cystein for
15 mn, followed by a 24 h chase. As shown in Fig. 4A and 4B,
wild type MMP-2 was stabler than mutated MMP-2. Indeed, after
8 h, approximately 40% of mutated forms were degraded (31.8%
for MMP-2C60/65A and 40.8% for MMP-2C233A) whereas wild
type MMP-2 was still intact. After 24 h, more than 60% of each
mutated forms were degraded (67.9% for MMP-2C60/65A and
62.3% for MMP-2C233A) whereas the wild type protein was
degraded about twice as less (33.9%). These results suggest that
mutated MMP-2 forms are more sensitive to degradation than the
wild type protein is.
MMP-2 epitope presentation from mutated MMP-2
constructs is mediated by the proteasome and depends
on a retro-translocation channel
Misfolded secretory proteins undergo retrograde transloca-
tion from the ER and are then hydrolyzed by the ER-associated
degradation pathway (ERAD) [19,20]. Two important compo-
nents of ERAD are the ubiquitin-proteasome system and the
retro-translocation channels allowing the transport of misfolded
proteins from the ER to the cytosol [21–23]. To ascertain
whether MMP-2 epitope presentation from the MMP-2 mutants
was dependent on these ERAD components, MMP-2 transfect-
ed COS cells were treated with the proteasome inhibitors MG-
132 or by the retrotranslocation channels inhibitor: Pseudomonas
aeruginosa Exotoxin-A [24,25]. Both inhibitors inhibited MMP-2
epitope presentation from MMP-2 constructs, however they had
no effect on the presentation of added synthetic 9-mer MMP-2
peptide (Figure 5A and B). These results indicate that the
degradation rate of mutated MMP-2 regulated by the ERAD
machinery directly affects MMP-2 immunogenicity.
Discussion
In this current work, we investigated the mechanisms
underlying the lack of MMP-2 epitope (560–568) presentation
via the classical endogenous pathway by MMP-2 cDNA construct
transfection into COS-7 cells and into tumor cells. In this
pathway, antigenic peptides derived from endogenous proteins
intersect the MHC class I biosynthetic pathway in the ER, where
MHC class I heavy chain and b2-microglobulin are synthesized.
These peptides are transported from the cytosol to the ER via the
transporter associated with antigen processing (TAP) complex
and loaded on nascent MHC class I molecule and b2-
microglobulin complexes [26,27]. Surprisingly we previously
reported that MMP-2 failed to be presented by this classical
endogenous pathway [9].
In 1–96, pre or pro deleted MMP-2, we eliminated a quite high
quantity of amino acids compared to mutated MMP-2, where only
one cysteine was replaced by an alanine. This probably induces a
higher deleted proteins misfolding compared to mutated proteins.
This can explain why deleted proteins have significantly better
endogenous presentation of MMP-2 antigen than cysteine
mutants. However, in this paper we showed that elimination of
Figure 3. Cystein deletion does not impede MMP-2 release.
COS-7 cells transfected with indicated plasmids were cultured for 48 h
without FCS. Supernatants were collected and equal amounts of
protein were loaded on SDS-PAGE. MMP-2 release was analyzed by (A)
gelatin zymographie and (B) western blotting. NT: untransfected COS-7
cells. Data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0011894.g003
Figure 4. Mutated MMP-2 proteins are more rapidly degraded than the wild-type enzyme. COS-7 cells transfected with indicated
plasmids were pulse-labeled with [
35S] methionine/cystein for 15 min and chased for 0–24 h. MMP-2 immunoprecipitates were separated by SDS-
PAGE and analyzed by autoradiography (A). Data were plotted to indicate the residual protein remaining where the amount of this protein at 0 h
time point was calculated to represent 100% of total MMP-2 in each case (B). Data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0011894.g004
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induce endogenous presentation of the MMP-2560–568 epitope.
Further more, we showed that the wild type MMP-2 protein is less
degraded than the mutated forms. We analyzed these proteins by
circular dichroism (CD). The results showed that the spectra of
MMP-2 mutants are found to be practically identical to the
spectrum of wild-type MMP-2 (data not shown). So, the CD
analysis confirms the protein folding and shows that the mutations
do not induced significant changes in the secondary structure of
mutated MMP-2. However, this absence of changes in secondary
structures does not exclude other conformational changes in the
whole MMP-2 protein. Indeed, based on MMP-2 crystal structure
(Morgunova et al., 1999) we learnt that disulfide bond C60–C65 is
located in the loop between the helix H1 and H2 of the
prodomain. This prodomain maintained MMP-2 as a zymogen
and this loop is cleaved by MMP-14 after MMP-2 secretion given
active form. Moreover disulfide bond C233–C247 is located in the
first Fibronectin type II domain and this domain is necessary for
substrate binding. So these two disulfide bonds seem to be located
in important regions for wild type MMP-2. These observations
and our experiments probably mean that, for wild type MMP-2,
quality control of these two regions is essential, so that none, or
few, misfolded enzymes are naturally produced and consequently
no, or few, MMP-2 epitope presentation occur. Altogether these
results suggest that MMP-2 folding has an inhibitory role on the
endogenous degradation of MMP-2 by the proteasome and its
subsequent immunogenicity.
Disulfide bond formation in the endoplasmic reticulum of
eukaryotic cells is catalyzed by the protein disulfide isomerase
(PDI) and other members of the thioredoxin family [28–30].
Disulfide bond formation takes part in protein folding, stability,
and activity [31–33]. Other studies provided molecular evidence
that intact disulfide bonds are critical for proteasome resistance.
Elimination of disulfide bonds in murine Proinsulin 2, in bovine
viral diarrhea virus E2 glycoproteins as well as in Human ABCG2
render these proteins sensitive to proteasomal degradation.
Nonetheless to our knowledge no proteasome derived peptides
from these proteins (murine Proinsulin 2, BVDV E2 glycoproteins
and human ABCG2) have been identified as targets of CTL [34–
36]. Even if we already know that disulfide bridges impede
Figure 5. MMP-2 endogenous presentation require proteasome and sec61. A and D: COS-7 cells were cotransfected with plasmids coding
for WT MMP-2 or mutated MMP-2 and for HLA-A*0201. 24 h later, COS-7 cells were treated with proteasome inhibitor MG-132 (A) or sec61 inhibitor
Exotoxin-A (D). After overnight incubation, cells were washed, counted and cocultured with M134.12 CTL clones (E/T ratio 1:3). The TNF response was
tested 6 h later on wehi-13 cells. B and E: cells treated as in A and D, were pulsed 1 h with peptide before coculture with M134.12. Peptide,
corresponding to the MMP-2560–568 epitope, was used as control of HLA-A*0201 surface expression. C and F: Inhibition percentages are expressed as
the percent TNF response of cells treated with drugs versus the percent TNF response of cells untreated, where TNF response of cells untreated was
normalized to 100%. Transfection efficiency was controlled with GFP transfected COS-7 cells. Data are representative of two independent
experiments. Error bars indicate standard deviations of triplicates.
doi:10.1371/journal.pone.0011894.g005
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shown to impeding CD8 T cell epitope generation.
In a similar way, the structural complexity of a protein and
especially the presence of disulfide bonds, seems to be critical for
MHC class II presentation. Indeed disulfide bond reduction of
proteins facilitates processing and presentation to antigen-specific
CD4 T cells [37–40]. To our knowledge little is known about the
impact of disulfide bond formation on endogenous MHC class I
presentation. The classical class I antigen processing pathway is
considered independent from 3D structure constraints since the
antigen pools from which MHC class I epitope are derived, mainly
come from unfolded protein or DRiPs [41–43]. Our previous
observation that a fraction of HLA-A*0201 tumor cell lines lacking
avb3 integrin expression and secreting MMP-2 protein was not
recognized by the specific T cell clone, led us to suggest that the
amount of unfolded form or DRiP containing the epitope are low
in these cells. However since our functional read-out involved a T
cell clone specific for an epitope localized in the C-terminal
extremity of MMP-2, we cannot formally rule out formation of
DRiPs or misfolded proteins from the N-terminal extremity of
MMP-2.
By preventing the formation of at least one disulfide bond, we
demonstrated that the redox status of MMP-2 significantly
increased its degradation and resulted in processing of the specific
T cell epitope by the endogenous pathway. Furthermore it did not
prevent MMP-2 secretion. Based on these findings, we propose
that disruption of one disulfide bond is detected by the quality
control mechanism present in the ER [22,44]. This mutation
would entail the reimportation of mutated MMP-2 from the
secretory pathway to the cytosol, where the protein is processed by
the ER-associated degradation (ERAD) machinery [19,22,45]. To
our knowledge these data would indicate that protein folding may
affects endogenous class I restricted T cell epitope generation.
According to this hypothesis, we propose in Fig. 6 a model
explaining why the MMP-2 epitope is normally presented only
through the cross-presentation pathway. In such a model, cells
secrete MMP-2 as an inactive zymogen (Pro-MMP-2) containing 8
disulphide bonds [11,12]. Owing to its highly stable conformation,
Pro-MMP-2 shows very limited degradation through the ERAD
pathway. Pro-MMP-2 is activated at the cell surface through a
multistep pathway that involves MMP-14 (MT1-MMP) and the
tissue inhibitor of metalloproteinases 2 (TIMP-2) [46]. Pro-MMP-
2 might also be activated by MMP-15 through a TIMP-2-
independent mechanism [47]. Pro-MMP-2 activation is associated
with proteolytic removal of the propeptide prodomain including
Cystein 60–65 disulfide bond [48]. In this regard, this activated
form could be detected by zymography in supernatants of all
melanoma cell lines that cross-presented the MMP-2 epitope 560–
568 (Godefroy personal communication). Activated MMP-2
containing only 7 disulfide bonds is then internalized in clathrin-
coated vesicles and subsequently by an unknown mechanism
reachs the cytosol for proteasome degradation. During protein
synthesis, MMP-2 acquired 8 disulfides bond in the ER, probably
impeding its retrotranslocation and its degradation by proteasome
and subsequently MMP-2560–568. epitope presentation by the
endogenous MHC class I pathway.
Figure 6. Hypothetical models for MMP-2560–568 epitope generation by cross-presentation and by endogenous pathway. Cross-
presentation (1): Newly synthesized wild-type MMP-2 acquire disulfide bonds in the endoplasmic reticulum (ER) before joining the secretory pathway.
In the extracellular environment, physiologic activation of the pro-MMP-2 induce the cleavage of the propeptide domain which contains a disulfide
bridge (C60-C65: unique to the MMP-2). MMP-2 active form then interact with the integrine avb3 and is internalized in clathrin-coated vesicle. Finally
MMP-2 is transported to the cytosol, in an unknown mechanism, and degraded by the proteasome. Peptides generated can reach the endogenous
pathway (peptides are transported in the ER through TAP, bind to HLA-A*0201 and transported to the cell surface). Endogenous presentation (2):
Mutated MMP-2 lacking a disulfide bond can’t join the secretory pathway and is retrotranslocated via Sec61. In the cytosol, mutated MMP-2 is
degraded by the proteasome and resulting peptides are loaded on MHC class I molecules.
doi:10.1371/journal.pone.0011894.g006
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through the degradation of the extracellular matrix and basal
membranes, in multiple physiological processes and in tumor
progression. Nevertheless, the MMP-2 epitope was found to be
cross-presented exclusively by melanoma cells and not presented
by the endogenous pathway [9]. All these characteristics point to
MMP-2 as the target of interest in melanoma immunotherapy
protocols.
Materials and Methods
Cell lines and culture medium
The CTL clone M134.12, melanoma cell line M117 were
established in our laboratory (Godefroy et al 2005). M134.12 was
obtained from Tumor Infiltrating Lymphocytes (TIL) of melano-
ma patient M134 by limiting dilution and selected for it specificity
against the antigen MMP-2 in an HLA-A*0201 context. Non-
small cell lung cancer cell line (1355) (established by H. Oie) was
gift from C. Saı ¨ (UMR 892 INSERM/Universite ´ de Nantes,
France). Mouse fibrosarcoma WEHI 164 clone 13 (established by
Rollinghoff and N.L. Warner) and COS-7 cells (established by Y.
Gluzman) were gifts from T. Boon (Ludwig Institute for Cancer
Research, Brussels, Belgium).
Tumor cell lines and COS-7 cell were maintained in RPMI-
1640 and DMEM 1 g glucose/L respectively, supplemented with
penicillin-streptomycin (100 U/ml and 10 mg/ml respectively), L-
Glutamine (2 mM) and 10% fetal calf serum (all from Sigma-
Aldrich). The CTL clone was maintained in RPMI-1640
supplemented with penicillin-streptomycin, L-Glutamine, IL-2
(150 U/ml) and 8% pooled human serum (pHS).
Ethics Statement
Written consents were obtained from all patients and healthy
donors. The local ethics committee ‘‘Comite ´ de Protection des
Personnes Ouest IV- Nantes’’ and the ‘‘Agence franc ¸aise de
se ´curite ´ sanitaire des produits de sante ´’’ approved all these studies.
Cloning of cDNA encoding modified MMP-2
NA-134A corresponding to the end of the MMP-2 sequence
and containing the epitope was obtained from a cDNA library of
melanoma cell line M134. Truncated MMP-2 D96MMP-2 was
obtained by PCR. DpreMMP-2 and DproMMP-2 were obtained
by deletion by PCR of the nucleotide sequence coding for the
signal peptide (Dpre) or the propeptide (Dpro). Point mutations
were introduced into the cDNA coding for MMP-2 using
directional mutagenesis: site-directed mutagenesis was performed
using primers with nucleotide substitutions in order to change
cystein in alanine at amino acid 60 and/or 65 and 233.
Each of the cDNA constructs was digested with EcoRI and
XbaI, inserted into pcDNA3.1 vector (Invitrogen) and plasmids
were electroporated into a bacterial strain (Escherichia coli TOP
10 F’).
Transient transfection of COS-7 cells
We used the DEAE-dextran-chloroquine method as described
(Brichard et al. 1993, Coolie et al. 1994).
Briefly: 1,5.10
4/well COS-7 cells were plated in flat-bottom 96
well plates. After 24 h cells were cotransfected with 125 ng of
plasmids containing the cDNA coding for the different constructs
of MMP-2 and with 125 ng of plasmids containing the cDNA
coding for HLA-A*0201. Each transfection condition was
performed in duplicate. After 48 h, cells were tested in a CTL
stimulation assay. Transfection efficiency was controlled by
transfected COS-7 cells with plasmid coding for the GFP and
measured by flow cytometry analysis.
Transfection of COS-7 cells using the Cell Line
Nucleofector
TM kit V from Amaxa
1.10
6 COS-7 cells were transfected with 5 mg of plasmid (coding
for mutated MMP-2) according to the manufacturer’s instructions.
For pulse-chase experiments, 7.10
6 COS-7 transfected with the
same plasmid were pooled in 100 mm dishes and cultured 48 h at
37uC before metabolic labeling.
For zymography and Western blotting assays, 1.10
6 transfected
COS-7 were plated in a 6-well plate. 1 day later, cells were washed
and cultured for 48 h in medium without FCS.
Transient transfection of tumor cell lines using
lipofectamine reagent
2.10
4/well tumor cell lines were plated in flat-bottom 96 wells
plates 24 h before transfection. Cells were washed with OPTI-
MEM medium (Invitrogen) and were transfected using lipofecta-
mine and Plus reagent (Invitrogen) and 100 ng of plasmid
containing the cDNA coding for the mutated MMP-2, in OPTI-
MEM. All transfection conditions were performed in duplicate.
After 48 h, cells were tested in a CTL stimulation assay.
Transfection efficiency was controlled by transfected tumor cells
with plasmid coding for the GFP and measured by flow cytometry
analysis.
Treatment of transfected COS-7 cells
COS-7 cells were transiently cotransfected with plasmids coding
for mutated MMP-2 and for HLA-A*0201 using DEAE-dextran-
chloroquine method. 24 h later, COS-7 cells were treated by
addition to the culture medium of 0,38 mM proteasome inhibitor
MG-132 (Calbiochem) or 3 mg/ml sec61 inhibitor Exotoxin A
(Sigma-Aldrich). After overnight incubation, cells were washed,
counted and tested in CTL stimulation assay.
CTL stimulation assay
Transfected cells were tested for their capability to present a
MMP-2 derived HLA-A*0201 and consequently to stimulate the
production of Tumor Necrosis Factor (TNF) by the specific CTL
M134.12.
1.10
4 CTL were added to 3.10
4 stimulator cells (transfected
tumoral or COS-7 cells) for 6 h at 37uC. Then, culture supernatants
were collected and TNF release by CTL was measured by testing
TNF cytotoxicity on WEHI164 clone 13 cells in a MTT colorimetric
assay (Espevik et al, 1986).
Gelatine substrate gel zymography
Secretion of MMP-2 was evaluated by gelatin zymography, as
previously described (Barille et al. 1999).
Supernatants were obtained from transfected COS-7 cells
(Amaxa) cultured in DMEM 1 g glucose/L without FCS during
48 h and total proteins concentrations were measured (BC Assay,
Interchim). 22,5 mg of total protein were mixed with sample buffer
without reducing agent and proteins were separated by SDS-
PAGE (7,5% acrylamide gels containing 0,2% gelatin). After
electrophoresis, SDS was removed from the gel by an incubation
in 2,5% triton X-100 for 1 h at room temperature. Gels were then
incubated in a buffer containing 50 mmol/L Tris-HCl, 5 mmol/L
CaCl2, pH 7,6 for 20 h at 37uC and stained with Coomassie blue
R250 for 30 min. Proteolytic activity of MMP-2 was evidenced as
a clear band against the blue background of stained gelatin.
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Supernatants were obtained from transfected COS-7 cells
(Amaxa) cultured in DMEM 1 g glucose/L without FCS during
48 h and total proteins concentrations were measured (BC Assay,
Interchim). 50 mg of total protein were mixed with sample buffer
containing reducing agent and proteins were separated by SDS-
PAGE (7,5% acrylamide), electrotransferred to polyvinylidene
difluoride (PVDF) membrane and blocked 1 h in 1% Western
Blocking Reagent (Roche Diagnostic) TBS 1X. Blots were probed
overnight at 4uC with a rabbit polyclonal antibody anti-MMP-2
hinge region (Biomol, Tebu-bio SAS, France), washed in TBS 1X,
0,1% Tween-20 and probed with HRP-conjugated anti-rabbit,
anti-mouse antibody (Roche). The signal was detected by
enhanced chemiluminescence detection (Perbio).
Pulse-chase experiments, immunoprecipitation and
SDS-PAGE
48 h after transfection using the Cell Line Nucleofector
TM kit V
(Amaxa), 7.10
6 transfected COS-7 were incubated at 37uC for
1 h30 in cystein and methionine-free DMEM 4,5 g glucose/L
(Invitrogen). Cells were then pulsed for 15 min with 350 mCi of
[
35S] methionine/cystein (GE Healthcare), plus Brefeldin A (BFA)
10 mg/ml (Sigma-Aldrich) in 5 ml of DMEM 4,5 g glucose/L
without cystein and methionine. Cells were then recovered and
redistributed: 1.10
6 cells in 2 ml of DMEM containing FCS plus
BFA, and chased from 0 to 24 h. After chase, cells were pelleted,
resuspended in lysis buffer (10 mM Tris-HCl pH 7,6, 150 mM
NaCl, 5 mM EDTA, 1 mM PMSF, 2 mg/ml aprotinin, 1% Triton
X-100) for 45 min on ice and centrifugated at 10000 g for 30 min
at 4uC. Protein concentration in supernatants was measured using
bicinchoninic acid (BCA Protein Assay, Pierce, Rockford, IL).
70 mg of lysates were precleared with protein G Agarose (Perbio)
and then immunoprecipitated overnight at 4uC with a rabbit
polyclonal antibody anti-MMP-2 (H-76, Santa-Cruz, Tebu-bio
SAS, France) and protein G agarose. Beads were pelleted, washed
and boiled in SDS sample buffer. Proteins in immunoprecipitated
samples were separated by SDS-PAGE (7,5% acrylamide) and
analyzed by autoradiography.
Statistical analysis
Statistical analysis was done with InStat 2.01. Data were
analyzed using ANOVA test. p,0.005 was considered significant.
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